Tolvaptan gets Japanese approval for expanded indication

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) said Japan's Ministry of Health, Labor and Welfare (MHLW) approved a label expansion for Samsca tolvaptan to include treatment of autosomal dominant polycystic kidney disease (ADPKD), a rare genetic disease characterized by non-malignant cysts in the kidneys. The vasopressin 2 (V2) receptor antagonist is approved in Japan to treat fluid retention in patients with hepatic cirrhosis and volume overload in patients with heart failure. ...